[go: up one dir, main page]

ZA200810850B - High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity - Google Patents

High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity

Info

Publication number
ZA200810850B
ZA200810850B ZA200810850A ZA200810850A ZA200810850B ZA 200810850 B ZA200810850 B ZA 200810850B ZA 200810850 A ZA200810850 A ZA 200810850A ZA 200810850 A ZA200810850 A ZA 200810850A ZA 200810850 B ZA200810850 B ZA 200810850B
Authority
ZA
South Africa
Prior art keywords
high affinity
humanized anti
reduced immunogenicity
blocking antibodies
affinity human
Prior art date
Application number
ZA200810850A
Other languages
English (en)
Inventor
Andreas Menrad
Joerg Willuda
Klaus Bosslet
Dieter Zopft
Heike Petrul
Stefan Steidl
Josef Prassler
Corinne Petit-Frere
Original Assignee
Bayer Schering Pharma Ag
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Morphosys Ag filed Critical Bayer Schering Pharma Ag
Publication of ZA200810850B publication Critical patent/ZA200810850B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
ZA200810850A 2006-05-24 2008-12-23 High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity ZA200810850B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06010779 2006-05-24

Publications (1)

Publication Number Publication Date
ZA200810850B true ZA200810850B (en) 2010-05-26

Family

ID=38659612

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200810850A ZA200810850B (en) 2006-05-24 2008-12-23 High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity

Country Status (23)

Country Link
US (1) US20090081207A1 (fr)
EP (1) EP2032605A2 (fr)
JP (1) JP2009537158A (fr)
KR (1) KR20090027218A (fr)
CN (1) CN101495515A (fr)
AR (1) AR061107A1 (fr)
AU (1) AU2007253586A1 (fr)
BR (1) BRPI0711796A2 (fr)
CA (1) CA2652886A1 (fr)
CL (1) CL2007001488A1 (fr)
CR (1) CR10456A (fr)
DO (2) DOP20070101A (fr)
EA (1) EA200802348A1 (fr)
EC (1) ECSP088909A (fr)
MA (1) MA30425B1 (fr)
MX (1) MX2008014910A (fr)
NO (1) NO20085362L (fr)
PE (1) PE20080100A1 (fr)
TN (1) TNSN08469A1 (fr)
TW (1) TW200817433A (fr)
UY (1) UY30362A1 (fr)
WO (1) WO2007134876A2 (fr)
ZA (1) ZA200810850B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2511298B1 (fr) 2005-10-31 2019-01-16 Oncomed Pharmaceuticals, Inc. Compositions et procédés pour le traitement du cancer utilisant des recepteurs FZD humains
CA2646611A1 (fr) 2006-03-21 2008-05-22 Genentech, Inc. Therapies combinatoires
HUE027911T2 (en) 2007-09-26 2016-11-28 Genentech Inc New antibodies
EP2650017A3 (fr) * 2008-02-05 2014-01-22 Bristol-Myers Squibb Company Anticorps Alpha 5 - bêta 1 et leurs utilisations
BRPI0919473A2 (pt) 2008-09-26 2017-08-29 Oncomed Pharm Inc Agentes de ligação frizzled e usos dos mesmos
US20110313134A1 (en) * 2008-11-06 2011-12-22 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
EP2379595A2 (fr) 2008-12-23 2011-10-26 AstraZeneca AB Agents de liaison ciblés dirigés contre 5 1 et leurs applications
CN102365297B (zh) * 2009-03-25 2014-10-29 霍夫曼-拉罗奇有限公司 新型抗-α5β1抗体及其应用
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
NZ602700A (en) 2010-04-01 2014-10-31 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
DK2933262T3 (en) * 2010-07-09 2018-06-25 Affibody Ab polypeptides
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EP2545905A1 (fr) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited Nouvelle composition thérapeutique contenant de l'apomorphine en tant que principe actif
CN104284679B (zh) 2012-03-13 2017-08-04 瑞斯比维特有限公司 药物制剂
JP2015536933A (ja) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
RU2681994C2 (ru) * 2012-12-26 2019-03-14 Онкосинерджи, Инк. КОМПОЗИЦИИ АНТИТЕЛА К ИНТЕГРИНУ β1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
ES2797901T3 (es) * 2015-06-28 2020-12-04 Allgenesis Biotherapeutics Inc Proteínas de fusión para la inhibición de angiogénesis
CN113557246B (zh) * 2019-07-24 2023-09-01 韩国基础科学支援研究院 靶向αvβ3整联蛋白的单域抗体
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013495A (en) * 1994-10-21 2000-01-11 The Scripps Research Institute Methods of use for integrin B1C cell growth inhibitor
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
WO2004056308A2 (fr) * 2002-11-26 2004-07-08 Protein Design Labs, Inc. Anticorps chimeriques et humanises diriges contre l'integrine $g(a)5$g(b)1 modulant l'angiogenese
AU2005226736B2 (en) * 2004-03-24 2009-11-26 Abbvie Biotherapeutics Inc. Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
CA2646611A1 (fr) * 2006-03-21 2008-05-22 Genentech, Inc. Therapies combinatoires

Also Published As

Publication number Publication date
MA30425B1 (fr) 2009-05-04
WO2007134876A2 (fr) 2007-11-29
AU2007253586A1 (en) 2007-11-29
KR20090027218A (ko) 2009-03-16
EP2032605A2 (fr) 2009-03-11
NO20085362L (no) 2009-02-23
CN101495515A (zh) 2009-07-29
DOP20070101A (es) 2007-12-30
WO2007134876A8 (fr) 2009-07-02
JP2009537158A (ja) 2009-10-29
BRPI0711796A2 (pt) 2011-12-06
US20090081207A1 (en) 2009-03-26
WO2007134876A3 (fr) 2008-03-27
TNSN08469A1 (en) 2010-04-14
CA2652886A1 (fr) 2007-11-29
PE20080100A1 (es) 2008-04-18
DOP2007000101A (es) 2007-12-31
AR061107A1 (es) 2008-08-06
TW200817433A (en) 2008-04-16
UY30362A1 (es) 2008-01-02
ECSP088909A (es) 2008-12-30
MX2008014910A (es) 2009-01-23
EA200802348A1 (ru) 2009-08-28
CL2007001488A1 (es) 2008-01-04
CR10456A (es) 2009-02-26

Similar Documents

Publication Publication Date Title
ZA200810850B (en) High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity
IL272883A (en) Monoclonal antibodies and their uses
HRP20181969T1 (hr) Humanizirana protutijela protiv čimbenika d i njihova upotreba
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
IL240245A0 (en) Antibodies against 5t4 and their uses
ZA200804148B (en) Anti-alpha2 integrin antibodies and their uses
IL194266A0 (en) Anti-igf-ir antibodies and uses thereof
SG10201501103RA (en) Antibodies And Immunoconjugates And Uses Therefor
ZA201002209B (en) Antibodies and immunoconjugates and uses therefor
ZA200807555B (en) Anti-TAT226 antibodies and immunoconjugates
ZA200809776B (en) Antibodies and immunoconjugates and uses therefor
IL187710A0 (en) Anti-trkb monoclonal antibodies and uses thereof
SI2061814T1 (sl) Protitelesa in imunokonjugati in njihove uporabe
IL203429A0 (en) Immunogenic polypeptides and monoclonal antibodies
EP2077325A4 (fr) Anticorps monoclonal et son utilisation